Skip Navigation


NDT Advance Access originally published online on May 5, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/7/1716    most recent
gfh219v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gross, O.
Right arrow Articles by Weber, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, O.
Right arrow Articles by Weber, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2004) 19: 1716-1723
Nephrol Dial Transplant Vol. 19 No. 7 © ERA-EDTA 2004; all rights reserved


Original Article

Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis

Oliver Gross1, Eckhard Schulze-Lohoff1, Marie-Louise Koepke1, Bogdan Beirowski2, Klaus Addicks2, Wilhelm Bloch2, Neil Smyth3 and Manfred Weber1

1 Medical Faculty University of Cologne, Department of Internal Medicine I, Cologne General Hospital, Merheim Medical Center, Cologne, Germany, 2 Department of Anatomy I, and 3 Center for Biochemistry, The Medical Faculty, University of Cologne, Cologne, Germany

Correspondence and offprint requests to: Dr O. Gross, Department of Internal Medicine I, Merheim Medical Center, Cologne General Hospital, Ostmerheimer Straße 200, D-51109 Cologne, Germany. Email: oliver.gross{at}uni-koeln.de

Background. Several studies have shown antifibrotic effects of angiotensin converting enzyme (ACE) inhibitors as well as of angiotensin receptor 1 (AT1) antagonists, however, prospective trials with clinical end points comparing these effects do not exist. COL4A3–/– mice develop a non-hypertensive progressive renal fibrosis. We used this animal model to compare the potential of ACE inhibitor vs AT1 antagonist to prevent renal fibrosis irrespective of blood pressure-dependent involvement by the renin system.

Methods. COL4A3–/– mice were treated with placebo, ramipril or candesartan. Blood pressure, proteinuria, serum urea and lifespan were monitored. Renal matrix was characterized by immuno-histochemistry, light and electron microscopy. Further biochemical analysis was provided using cDNA microarray and western blot techniques.

Results. Untreated mice died of renal failure after 71±6 days. Ramipril and candesartan both delayed onset and reduced the extent of proteinuria. Both had minor effects on blood pressure and postponed onset of uraemia. Ramipril increased lifespan by 111% to 150±21 days (P<0.01), whereas candesartan resulted in only a 38% prolongation to 98±16 days (P<0.01). Ramipril reduced glomerular and tubulo-interstitial fibrosis and numbers of activated fibroblasts to a greater extent than candesartan. Microarray and western blot analysis revealed a higher antifibrotic potential of ramipril in terms of downregulation of TGFß, connective tissue growth factor, metalloproteinases and extracellular matrix proteins.

Conclusions. The results indicate an antifibrotic, nephroprotective effect of ACE inhibitors and AT1 antagonists in an animal model of progressive renal fibrosis. The greater antifibrotic effect of ramipril at the maximal therapeutic doses employed may not be explained by different antiproteinuric or blood pressure lowering properties, but by—in contrast to candesartan—its ability to hinder the proinflammatory, profibrotic activation of the angiotensin receptor 2.

Keywords: angiotensin; collagen; fibrinogen; renal hypertension; renal hypertension


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
E. I. Ager, J. Neo, and C. Christophi
The renin-angiotensin system and malignancy
Carcinogenesis, September 1, 2008; 29(9): 1675 - 1684.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
K. Katayama, M. Kawano, I. Naito, H. Ishikawa, Y. Sado, N. Asakawa, T. Murata, K. Oosugi, M. Kiyohara, E. Ishikawa, et al.
Irradiation Prolongs Survival of Alport Mice
J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1692 - 1700.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
F. Omasu, T. Oda, M. Yamada, N. Yoshizawa, K. Yamakami, Y. Sakurai, and S. Miura
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats
Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1292 - F1298.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
B. Beirowski, M. Weber, and O. Gross
Chronic Renal Failure and Shortened Lifespan in COL4A3+/- Mice: An Animal Model for Thin Basement Membrane Nephropathy
J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1986 - 1994.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.